Table 1.
Baseline characteristics for patients included in the cohort study between 1991 and 2013 with a median follow‐up of 3 years
| Characteristic | Clarithromycin containing HPT regime | Clarithromycin‐free HPT regime |
|---|---|---|
| n (%) | n (%) | |
| Gender | ||
| Male | 12386 (47.6%) | 1196 (47.4%) |
| Female | 13643 (52.4%) | 1327 (52.6%) |
| Age | ||
| 0–40 years | 6114 (23.5%) | 592 (23.5%) |
| 40–50 years | 5365 (20.6%) | 518 (20.5%) |
| 50–60 years | 5343 (20.5%) | 529 (21.0%) |
| 60–70 years | 4976 (19.1%) | 478 (19.0%) |
| 70–80 years | 3135 (12.0%) | 301 (11.9%) |
| >80 years | 1096 (4.2%) | 105 (4.2%) |
| Smoking status | ||
| non‐smoker | 10392 (39.9%) | 1052 (41.7%) |
| current smoker | 7409 (28.5%) | 632 (25.1%) |
| ex‐smoker | 7884 (30.3%) | 812 (32.2%) |
| unknown | 344 (1.3%) | 27 (1.1%) |
| Alcohol status | ||
| non‐drinker | 4330 (16.6%) | 442 (17.5%) |
| ex‐drinker | 1133 (4.4%) | 120 (4.8%) |
| current drinker (unknown quantity) | 102 (0.4%) | 11 (0.4%) |
| <2 u day–1 | 4387 (16.9%) | 447 (17.7%) |
| 3‐6 u day–1 | 10900 (41.9%) | 1016 (40.3%) |
| >6 u day–1 | 2588 (9.9%) | 234 (9.3%) |
| unknown | 2589 (10.0%) | 253 (10.0%) |
| Body mass index (kg m−2) | ||
| normal (18.5–25) | 9642 (37.0%) | 941 (37.3%) |
| overweight (25–30) | 8884 (34.1%) | 856 (33.9%) |
| obese I (30–35) | 3585 (13.8%) | 367 (14.6%) |
| obese II (35–40) | 1109 (4.3%) | 115 (4.6%) |
| obese III (>40) | 472 (1.8%) | 44 (1.7%) |
| unknown | 2337 (9.0%) | 1200 (7.9%) |
| Consulted GP in year before exposure | 25948 (99.7%) | 2514 (99.6%) |
| History of cardiovascular disease | 4226 (16.2%) | 366 (14.5%) |
| History of heart failure | 755 (2.9%) | 59 (2.3%) |
| History of arrhythmia | 1434 (5.5%) | 127 (5.0%) |
| History of hypertension | 8240 (31.7%) | 783 (31.0%) |
| History of COPD | 1682 (6.5%) | 167 (6.6%) |
| History of asthma | 3615 (13.9%) | 350 (13.9%) |
| History of hyperlipidaemia | 4605 (17.7%) | 416 (16.5%) |
| History of diabetes mellitus | 3734 (14.4%) | 342 (13.6%) |
| History of cancer | 4884 (18.8%) | 461 (18.3%) |
| History of NSAID use | 1942 (7.5%) | 167 (6.6%) |
| History of oral corticosteroid use | 383 (1.5%) | 36 (1.4%) |
| History of antipsychotic use | 854 (3.3%) | 81 (3.2%) |
| History of antidepressant use | 3101 (11.9%) | 294 (11.7%) |
| History of lipid lowering drug use | 2948 (11.3%) | 336 (13.3%) |
| History of anticoagulant use | 226 (0.9%) | 32 (1.3%) |
| History of antiplatelet use | 2156 (8.3%) | 242 (9.6%) |
| History of nitrate use | 649 (2.5%) | 56 (2.2%) |
| History of digoxin use | 146 (0.6%) | 15 (0.6%) |
| History of antiarrhythmic drug use | 59 (0.2%) | 6 (0.2%) |
| History of β‐adrenoceptor blocker use | 2192 (8.4%) | 230 (9.1%) |
| History of thiazide diuretic use | 1892 (7.3%) | 181 (7.2%) |
| History of calcium channel blocker use | 2072 (8.0%) | 216 (8.6%) |
| History of ACEI/ARB use | 2843 (10.9%) | 316 (12.5%) |
| History of loop diuretic use | 718 (2.8%) | 62 (2.5%) |
| Total | 26029 | 2523 |
ACEI angiotensinc enzyme inhibitor, ARB angiotensin receptor blocker, COPD chronic obstructive pulmonary disease, HPT Helicobacter pylori treatment, NSAID non‐steroidal anti‐inflammatory drug